

Onconova Therapeutics, Inc.
Form SC 13G/A
February 14, 2018

THE UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Onconova Therapeutics, INC.

(Name of Issuer)

Common STOCK, \$0.01 par value PER SHARE

(Title of Class of Securities)

68232V306

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. 68232V306

(1) Names of Reporting

Persons.

Tyndall
Capital
Partners,
L.P.

(2) Check the
Appropriate

Box if a (a) ☐

Member of a
Group

(b) ☐

(3) SEC Use Only

(4) Citizenship or Place of

Organization: State of Delaware

(5) Sole

Number of Voting Shares 1,387,646*

Power:

(6) Shared

Voting 0*

Power:

(7) Sole

By Dispositive 1,387,646*

Each Power:

(8) Shared

Dispositive 0*

With Power:

(9) Aggregate Amount Beneficially Owned by Each Reporting Person: 1,387,646*

(10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):

(11) Percent of Class Represented by Amount in Row (9): 12.4%*

(12) Type of Reporting Person (See Instructions): PN

*Based on 10,771,163 shares of common stock, par value \$0.01 per share (the "Shares"), of Onconova Therapeutics, Inc. (the "Company"), outstanding as of December 31, 2017, based on information from the Company and other publicly available information. As of December 31, 2017, Tyndall Partners, L.P., a Delaware limited partnership ("Tyndall") held 997,022 Shares and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall, and possesses the sole power to vote and the sole power to direct the disposition of all Shares held by Tyndall.

Item 1(a). Name Of Issuer:

Onconova Therapeutics, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

375 Pheasant Run

Newtown, PA 18940

Item 2(a). Name of Person Filing:

Tyndall Capital Partners, L.P.

Item 2(b). Address of Principal Business Office or, if None, Residence:

405 Park Avenue, Suite 1104

New York, New York 10022

Item 2(c). Citizenship:

State of Delaware

Item 2(d). Title of Class of Securities:

Common Stock, \$0.01 par value per share

Item 2(e). CUSIP No.:

68232V306

Item 3. If This Statement Is Filed

Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a:

Not Applicable.

Item 4. Ownership

(a) Amount Beneficially Owned:	1,387,646*
(b) Percent of Class:	12.4%*
(c) Number of Shares as to which such person has:	
(i) Sole power to vote or to direct the vote:	1,387,646*
(ii) Shared power to vote or to direct the vote:	0*
(iii) Sole power to dispose or to direct the disposition of:	1,387,646*
(iv) Shared power to dispose or to direct the disposition of:	0*

*Based on 10,771,163 shares of common stock, par value \$0.01 per share (the “Shares”), of Onconova Therapeutics, Inc. (the “Company”), outstanding as of December 31, 2017, based on information from the Company and other publicly available information. As of December 31, 2017, Tyndall Partners, L.P., a Delaware limited partnership (“Tyndall”) held 997,022 Shares and warrants to purchase up to 390,624 Shares. Tyndall Capital Partners, L.P. is the general partner of Tyndall, and possesses the sole power to vote and the sole power to direct the disposition of all Shares held by Tyndall.

Item

**5. Ownership of
Five Percent or
Less of a Class**

Not Applicable.

Item

**6. Ownership of
More Than Five
Percent on
Behalf of**

Another Person

Not Applicable.

Item

**7. Identification
and**

**Classification of
the Subsidiary
Which Acquired
the Security**

**Being Reported
on by the Parent
Holding**

**Company or
Control Person**

Not Applicable.

Item

**8. Identification
and**

**Classification of
Members of the
Group**

Not Applicable.

**Item 9. Notice of
Dissolution of
Group**

Not Applicable.

Item

10. Certification

By signing below

I certify that, to
the best of my
knowledge and
belief, the
securities referred
to above were not
acquired and are
not held for the
purpose of or with
the effect of

changing or
influencing the
control of the
issuer of the
securities and
were not acquired
and are not held in
connection with or
as a participant in
any transaction
having that
purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2018

**TYNDALL CAPITAL
PARTNERS, L.P.**

JEFFREY
MANAGEMENT,
By: LLC,

its general partner

By: /s/ Jeffrey S. Hallis
Jeffrey S. Hallis
Manager

**Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).**